Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort


Por: Alvarenga, JM, Yeung, JS, Prajapati, V, Ribero, S, Balato, A, Marzano, AV, Cruz, MJ, Lopes, MJP, Lazaridou, E, Carrascosa, JM, Farinha, P, Duarte, B, Sood, S, Rankin, BD, Ortoncelli, M, Caccavale, S, Ferrucci, SM, Rosa, GP, Daponte, AI, Silvi, G, Peris, K, Gori, N, Herranz, P, Prignano, F, Kolios, A, Rompoti, N, Gregoriou, S, Gkalpakiotis, S, Chiricozzi, A and Torres, T

Publicada: 1 feb 2026 Ahead of Print: 1 ene 2026
Resumen:
Introduction. Randomized clinical trials (RCTs) in atopic dermatitis (AD) often exclude older adults and patients with comorbidities, limiting the generalizability of trial findings to real-world populations. Despite the growing use of biologics and Janus kinase inhibitors (JAKis) in clinical practice, the extent to which real-world patients meet RCT eligibility criteria and their associated safety outcomes remains unclear. Methods. We conducted a retrospective analysis of a large, multicenter international cohort of adolescents and adults with AD treated with biologics (dupilumab, tralokinumab) or systemic JAKis (abrocitinib, baricitinib, upadacitinib) between October 2017 and March 2023 across 16 dermatology centers. Eligibility was defined according to commonly applied RCT criteria. Patients meeting >= 1 exclusion criterion were classified as ineligible. Demographic, clinical, and safety outcomes were analyzed. Results. Among 2154 patients, 514 (23.9%) were ineligible. The most frequent reasons were Eczema Area and Severity Index (EASI) < 16 (67.9%), age >= 75 years (21.8%), and cardiovascular disease (13.0%). Ineligibility patterns differed across treatments: patients receiving JAKis were most often ineligible because of EASI < 16 (92.8%), whereas ineligibility among biologic users more commonly reflected also age or cardiovascular comorbidity. Ineligible patients were older, had more non-atopic comorbidities, and had lower measured baseline disease activity.Safety profiles were generally favorable. Among biologic-treated patients, adverse event rates were similar between eligible and ineligible groups. In the JAKi cohort, overall adverse events were more frequent in ineligible patients (52.9% vs. 42.6%; p = 0.051), with acneiform eruption and lipid abnormalities emerging as the most distinct differences. No unexpected safety signals were identified in either treatment group. Conclusion. Nearly one-quarter of real-world patients with AD would not have met eligibility criteria for pivotal RCTs, yet both biologics and JAK inhibitors demonstrated acceptable safety profiles in these populations. While adverse events were more frequent among ineligible patients receiving JAKis, findings require further investigation to determine their clinical relevance, particularly regarding long-term cardiovascular outcomes.

Filiaciones:
Alvarenga, JM:
 Unidade Local Saude Santo Antonio Porto, Dept Dermatol, Rua Dom Manuel II 57, P-4050342 Porto, Portugal

Yeung, JS:
 Univ Toronto, Dept Med, Div Dermatol, Toronto, ON, Canada

 Womens Coll Hosp, Dept Med, Div Dermatol, Toronto, ON, Canada

 Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada

 Prob Med Res, Toronto, ON, Canada

Prajapati, V:
 Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada

 Dermatol Res Inst, Calgary, AB, Canada

 Skin Hlth & Wellness Ctr, Calgary, AB, Canada

 Prob Med Res, Calgary, AB, Canada

Ribero, S:
 Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy

Balato, A:
 Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

Marzano, AV:
 Fdn IRCCS CaGranda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

 Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

Cruz, MJ:
 Unidade Local Saude Sao Joao, Dept Dermatol, Porto, Portugal

 Univ Porto, Fac Med, Porto, Portugal

Lopes, MJP:
 Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal

Lazaridou, E:
 Aristotle Univ Thessaloniki, Sch Med, Dept Dermatol Venereol, Thessaloniki, Greece

:
 Hosp Univ Germans Trias i Pujol, Serv Dermatol, Badalona, Barcelona, Spain

Farinha, P:
 Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal

Duarte, B:
 Unidade Local Saude Sao Jose, Dermatol Dept, Lisbon, Portugal

Sood, S:
 Univ Toronto, Temerty Fac Med, Toronto, ON, Canada

Rankin, BD:
 Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada

Ortoncelli, M:
 Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy

Caccavale, S:
 Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

Ferrucci, SM:
 Fdn IRCCS CaGranda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

Rosa, GP:
 Unidade Local Saude Sao Joao, Dept Dermatol, Porto, Portugal

 Univ Porto, Fac Med, Porto, Portugal

Daponte, AI:
 Aristotle Univ Thessaloniki, Sch Med, Dept Dermatol Venereol, Thessaloniki, Greece

Silvi, G:
 Univ Florence, Dept Hlth Sci, Dermatol Sect, Florence, Italy

Peris, K:
 Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy

 Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy

Gori, N:
 Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy

 Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy

Herranz, P:
 Hosp La Paz, Dept Dermatol, Madrid, Spain

Prignano, F:
 Univ Florence, Dept Hlth Sci, Dermatol Sect, Florence, Italy

Kolios, A:
 Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland

Rompoti, N:
 Natl & Kapodistrian Univ Athens, A Sygros Hospital Skin & Venereal Dis, Fac Med, Dept Dermatol Venereol, Athens, Greece

Gregoriou, S:
 Natl & Kapodistrian Univ Athens, A Sygros Hospital Skin & Venereal Dis, Fac Med, Dept Dermatol Venereol, Athens, Greece

Gkalpakiotis, S:
 Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Dept Dermatovenereol, Prague, Czech Republic

 Charles Univ Prague, Fac Med 3, Prague, Czech Republic

Chiricozzi, A:
 Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Dermatol, Rome, Italy

 Fdn Policlin Univ A Gemelli IRCCS, UOC Dermatol, Dipartimento Sci Med & Chirurg, Rome, Italy

Torres, T:
 Unidade Local Saude Santo Antonio Porto, Dept Dermatol, Rua Dom Manuel II 57, P-4050342 Porto, Portugal

 Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal
ISSN: 21938210





Dermatology and Therapy
Editorial
Springer Verlag, 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND, Reino Unido
Tipo de documento: Article
Volumen: 16 Número: 2
Páginas: 1399-1409
WOS Id: 001654274500001
ID de PubMed: 41491444
imagen Green Submitted, gold

MÉTRICAS